Lipocine doses first participant in Phase 3 BLOOM study of oral brexanolone for postpartum depression
Lipocine Inc. has administered the initial dose in its Phase 3 BLOOM trial of LPCN 1154, a 48‑hour oral brexanolone formulation for postpartum depression. The placebo‑controlled outpatient study plans to enroll about 120 patients and will measure change from baseline on the 17‑item Hamilton Depression Rating Scale at 60 hours after dosing. Topline results are slated for the second half of 2027, and the data are intended to support a potential New Drug Application under the 505(b)(2) pathway.
Why it matters
The company says the trial data will be used to file an NDA, so a positive outcome could create a new FDA‑approved therapy and move the stock higher (Lipocine press release). Investors will watch the 2027 readout for any impact on the company’s valuation.
Key facts
- 1Lipocine dosed the first participant in the BLOOM Phase 3 study of LPCN 1154. prnewswire.com
- 2The study plans to enroll approximately 120 participants. prnewswire.com
- 3Topline results are expected in the second half of 2027. prnewswire.com
- 4BLOOM is a placebo‑controlled outpatient trial evaluating a 48‑hour oral dosing regimen. prnewswire.com
- 5The primary efficacy endpoint is change from baseline in the 17‑item Hamilton Depression Rating Scale (HAM‑D17) total score at 60 hours after dosing. clinicaltrialsarena.com
- 6Lipocine aims to use the data to support a potential New Drug Application under the 505(b)(2) pathway. prnewswire.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.